iPSC-healthy-AFC-001
IPi001-A
General
Cell Line |
|
| hPSCreg name | IPi001-A |
| Cite as: | IPi001-A (RRID:CVCL_C1QC) |
| Alternative name(s) |
iPSC-healthy-AFC-001
|
| Cell line type | Human induced pluripotent stem cell (hiPSC) |
| Similar lines | |
| Last update | 13th July 2023 |
| Notes | hiPSC line from healthy amniotic fluid cells reprogrammed by the Yamanaka/Sendai method. |
| User feedback | |
Provider |
|
| Generator |
Institut Pasteur (IP)
Contact:
Institut Pasteur (IP) |
| Owner | Institut Pasteur (IP) |
| Derivation country | France |
External Databases |
|
| BioSamples | SAMEA10401758 |
| Cellosaurus | CVCL_C1QC |
| Wikidata | Q114311742 |
General Information |
|
| Publications |
|
| * Is the cell line readily obtainable for third parties? |
Yes Research use: allowed
Clinical use: not allowed
Commercial use: not allowed
|
Donor Information
General Donor Information |
|
| Sex | male |
| Ethnicity | Caucasian |
Phenotype and Disease related information (Donor) |
|
| Diseases | No disease was diagnosed.
|
Karyotyping (Donor) |
|
| Has the donor karyotype been analysed? |
Yes
Normal
|
Donor Relations |
|
| Other cell lines of this donor | |
External Databases (Donor) |
|
| BioSamples | SAMEA10401782 |
Ethics
| Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
| Was the consent voluntarily given? | Yes |
| Has the donor been informed that participation will not directly influence their personal treatment? | Yes |
| Can you provide us with a copy of the Donor Information Sheet provided to the donor? | Yes |
| Do you (Depositor/Provider) hold the original Donor Consent Form? | No |
| If you do not hold the Donor Consent Form, do you know who does? | Yes |
| Is there other documentation provided to the donor for consenting purposes? | Yes |
| Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | anonymised |
| Does consent explicitly allow the derivation of pluripotent stem cells? | Yes |
| Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
| How may genetic information associated with the cell line be accessed? | Controlled Access |
| Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes |
| Name of accrediting authority involved? | CPP Ile de France |
| Approval number | DC 2015-2595 and 2016-A00773-48 |
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? |
hIPSC Derivation
General |
|
| Source cell type |
The fluid within the amniotic cavity which surrounds and protects the developing embryo. It is initially produced by the amnion and then later by the lungs and kidneys. The amount at term normally varies from 500 to 2000 ml.
Synonyms
|
Reprogramming method |
|
| Vector type | Non-integrating |
| Vector | Sendai virus |
Vector free reprogramming |
|
Other |
|
| Derived under xeno-free conditions |
Unknown |
| Derived under GMP? |
Unknown |
| Available as clinical grade? |
Unknown |
Culture Conditions
| Medium |
mTeSR™ Plus
|
Characterisation
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
| POU5F1 (OCT-4) |
Yes |
|
||||
| SOX2 |
Yes |
|
||||
| Alkaline Phosphatase |
Yes |
|
Differentiation Potency
Genotyping
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
Yes
arr(1-22)x2, XYx1
Karyotyping method:
Molecular karyotyping by SNP array
http:// |
Other Genotyping (Cell Line) |
|
Login to share your feedback, experiences or results with the research community.